Literature DB >> 3931594

Hypercalcemia in critically ill surgical patients.

J Forster, L Querusio, K W Burchard, D S Gann.   

Abstract

Critical surgical illness, commonly accompanied by shock, sepsis, multiple transfusions, and renal failure, is usually associated with low total calcium and/or low or normal ionized calcium. A seminal case of hypercalcemia in a surgical intensive care unit (SICU) patient prompted the review of 100 patients with longer than average SICU days (greater than 12) to determine the incidence, associated factors, and possible etiologies of this condition. Ten patients had elevated measured, and five others had elevated calculated, ionized calcium (5.9 +/- 0.25 mg%), an incidence of 15%. Compared to the 85 patients who did not develop hypercalcemia, this population had a significantly higher frequency of the following: renal failure, dialysis, total parenteral nutrition (TPN) usage greater than 21 days, bacteremic days greater than 1, transfusions greater than 24 units, shock greater than 1 day, SICU days greater than 36, and antibiotics used greater than 7. In addition, this group had significantly more days of hypocalcemia early in their hospital course. There was no difference in sex, age, mortality, or incidence of respiratory failure. Two patients studied in depth had renal failure requiring dialysis and no malignancy, milk-alkali syndrome, hyperthyroidism, or hypoadrenalism. Parathormone (PTH) concentrations were high normal or elevated (N terminal 20 and 21 pg/ml; C terminal 130 microliters Eq/ml and 1009 pg/ml) at the time of elevated calcium (total 9.2 to 14.6 mg%; ionized 4.9 to 8.2 mg%). Immobilization does not increase PTH. In renal failure, PTH elevation is a consequence of hypocalcemia rather than hypercalcemia. Moreover, five patients did not have renal failure. Shock, sepsis, and multiple transfusions containing citrate may lower total and/or ionized calcium and thus stimulate PTH secretion. Whatever the mechanism, approximately 15% of critically ill surgical patients develop hypercalcemia, which may represent a new form of hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3931594      PMCID: PMC1250954          DOI: 10.1097/00000658-198510000-00011

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  30 in total

1.  The cardiovascular effects of low levels of ionized calcium during massive transfusion.

Authors:  W S Howland; O Schweizer; G C Carlon; P L Goldiner
Journal:  Surg Gynecol Obstet       Date:  1977-10

2.  Immobilization hypercalcemia: a case report and review of the literature.

Authors:  A W Wolf; R G Chuinard; R S Riggins; R M Walter; T Depner
Journal:  Clin Orthop Relat Res       Date:  1976 Jul-Aug       Impact factor: 4.176

3.  Low plasma ionized calcium and response to calcium therapy in critically ill man.

Authors:  L J Drop; M B Laver
Journal:  Anesthesiology       Date:  1975-09       Impact factor: 7.892

4.  Parathyroid hormone and the hypercalcemia of immobilization.

Authors:  S Lerman; J M Canterbury; E Reiss
Journal:  J Clin Endocrinol Metab       Date:  1977-09       Impact factor: 5.958

5.  Hypercalcemia of acute renal failure. Clinical significance and pathogenesis.

Authors:  A de Torrente; T Berl; P D Cohn; E Kawamoto; P Hertz; R W Schrier
Journal:  Am J Med       Date:  1976-07       Impact factor: 4.965

6.  Hypercalcemia during the diuretic phase of acute renal failure.

Authors:  A J Segal; M Miller; A M Moses
Journal:  Ann Intern Med       Date:  1968-05       Impact factor: 25.391

7.  Hypercalcemia following acute renal failure.

Authors:  R W Turkington; H K Delcher; F A Neelon; H J Gitelman
Journal:  J Clin Endocrinol Metab       Date:  1968-08       Impact factor: 5.958

8.  Hypercalcemia in diuretic phase of acute renal failure.

Authors:  A Leonard; R J Nelms
Journal:  Ann Intern Med       Date:  1970-07       Impact factor: 25.391

9.  Hypercalcemia complicating immobilization in the treatment of fractures. A case report.

Authors:  J L Winters; A G Kleinschmidt; J J Frensilli; M Sutton
Journal:  J Bone Joint Surg Am       Date:  1966-09       Impact factor: 5.284

10.  Calcium metabolism and parathyroid function in primary aldosteronism.

Authors:  L M Resnick; J H Laragh
Journal:  Am J Med       Date:  1985-03       Impact factor: 4.965

View more
  7 in total

1.  Ionized calcium, parathormone, and mortality in critically ill surgical patients.

Authors:  K W Burchard; D S Gann; J Colliton; J Forster
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

2.  Variation in serum ionized calcium on cardiopulmonary resuscitation.

Authors:  S Gando; I Tedo; H Tujinaga; M Kubota
Journal:  J Anesth       Date:  1988-09-01       Impact factor: 2.078

3.  Risk Factors for Sepsis Based on Sepsis-3 Criteria after Orthotopic Liver Transplantation.

Authors:  Yanling Wang; Yu Gu; Fei Huang; Dezhao Liu; Zheng Zhang; Niman Zhou; Jiani Liang; Changyin Lu; Dongdong Yuan; Ziqing Hei
Journal:  Mediators Inflamm       Date:  2018-06-20       Impact factor: 4.711

4.  Epidemiology, clinical features, and management of severe hypercalcemia in critically ill patients.

Authors:  Cyril Mousseaux; Axelle Dupont; Cédric Rafat; Kenneth Ekpe; Etienne Ghrenassia; Lionel Kerhuel; Fanny Ardisson; Eric Mariotte; Virginie Lemiale; Benoît Schlemmer; Elie Azoulay; Lara Zafrani
Journal:  Ann Intensive Care       Date:  2019-11-27       Impact factor: 6.925

5.  Predictive value of ionized calcium in critically ill patients: an analysis of a large clinical database MIMIC II.

Authors:  Zhongheng Zhang; Xiao Xu; Hongying Ni; Hongsheng Deng
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

6.  New Predictive Equations for Serum Ionized Calcium in Hospitalized Patients.

Authors:  Javier Mateu-de Antonio
Journal:  Med Princ Pract       Date:  2015-12-07       Impact factor: 1.927

7.  Association of Initial Serum Total Calcium Concentration with Mortality in Critical Illness.

Authors:  Benji Wang; Yuqiang Gong; Binyu Ying; Bihuan Cheng
Journal:  Biomed Res Int       Date:  2018-06-26       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.